Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius

Executive Summary

Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.

You may also be interested in...



Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?

Hours after Merck revealed a merger agreement with Cubist, a court ruled that generic versions of Cubist’s big seller Cubicin can launch in 2016, two years earlier than expected, putting the pressure on Merck to justify the pricey acquisition.

Merck Pays Big To Expand Into Acute Care With Cubist Acquisition (Updated)

Merck agreed to pay $9.5 billion to acquire Cubist, gaining a portfolio of antibiotics for hard-to-treat infections as part of a broader strategy to expand in the acute care setting.

Cubist Leadership Transitions To Perez With ‘Strong Hand To Play’

President and Chief Operating Officer Robert Perez will succeed Michael Bonney as CEO effective Jan. 1, taking over the top leadership spot at a time when the specialty pharma is in the midst of a transformation into a multi-asset company.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel